416 related articles for article (PubMed ID: 24882610)
1. Stimulation of postsynapse adrenergic α2A receptor improves attention/cognition performance in an animal model of attention deficit hyperactivity disorder.
Kawaura K; Karasawa J; Chaki S; Hikichi H
Behav Brain Res; 2014 Aug; 270():349-56. PubMed ID: 24882610
[TBL] [Abstract][Full Text] [Related]
2. Comparison of SHR, WKY and Wistar rats in different behavioural animal models: effect of dopamine D1 and alpha2 agonists.
Langen B; Dost R
Atten Defic Hyperact Disord; 2011 Mar; 3(1):1-12. PubMed ID: 21432613
[TBL] [Abstract][Full Text] [Related]
3. The anticonvulsant and proconvulsant effects of alpha2-adrenoreceptor agonists are mediated by distinct populations of alpha2A-adrenoreceptors.
Szot P; Lester M; Laughlin ML; Palmiter RD; Liles LC; Weinshenker D
Neuroscience; 2004; 126(3):795-803. PubMed ID: 15183527
[TBL] [Abstract][Full Text] [Related]
4. Systemic administration of guanfacine improves food-motivated impulsive choice behavior primarily via direct stimulation of postsynaptic α
Nishitomi K; Yano K; Kobayashi M; Jino K; Kano T; Horiguchi N; Shinohara S; Hasegawa M
Behav Brain Res; 2018 Jun; 345():21-29. PubMed ID: 29476896
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of alpha2-adrenoceptors suppresses excitatory synaptic transmission in the medial prefrontal cortex of rat.
Ji XH; Ji JZ; Zhang H; Li BM
Neuropsychopharmacology; 2008 Aug; 33(9):2263-71. PubMed ID: 17957212
[TBL] [Abstract][Full Text] [Related]
6. Nicotine-stimulated release of [3H]norepinephrine is reduced in the hippocampus of an animal model of attention-deficit/hyperactivity disorder, the spontaneously hypertensive rat.
Sterley TL; Howells FM; Russell VA
Brain Res; 2014 Jul; 1572():1-10. PubMed ID: 24833064
[TBL] [Abstract][Full Text] [Related]
7. Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine.
Franowicz JS; Kessler LE; Borja CM; Kobilka BK; Limbird LE; Arnsten AF
J Neurosci; 2002 Oct; 22(19):8771-7. PubMed ID: 12351753
[TBL] [Abstract][Full Text] [Related]
8. Impaired visuospatial divided attention in the spontaneously hypertensive rat.
Jentsch JD
Behav Brain Res; 2005 Feb; 157(2):323-30. PubMed ID: 15639183
[TBL] [Abstract][Full Text] [Related]
9. The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.
Sallee FR
Postgrad Med; 2010 Sep; 122(5):78-87. PubMed ID: 20861591
[TBL] [Abstract][Full Text] [Related]
10. Methylphenidate and venlafaxine attenuate locomotion in spontaneously hypertensive rats, an animal model of attention-deficit/hyperactivity disorder, through α2-adrenoceptor activation.
Umehara M; Ago Y; Kawanai T; Fujita K; Hiramatsu N; Takuma K; Matsuda T
Behav Pharmacol; 2013 Aug; 24(4):328-31. PubMed ID: 23751518
[TBL] [Abstract][Full Text] [Related]
11. Oroxylin A improves attention deficit hyperactivity disorder-like behaviors in the spontaneously hypertensive rat and inhibits reuptake of dopamine in vitro.
Yoon SY; dela Peña I; Kim SM; Woo TS; Shin CY; Son KH; Park H; Lee YS; Ryu JH; Jin M; Kim KM; Cheong JH
Arch Pharm Res; 2013 Jan; 36(1):134-40. PubMed ID: 23371806
[TBL] [Abstract][Full Text] [Related]
12. Blockade of α2-adrenergic receptors in prelimbic cortex: impact on cocaine self-administration in adult spontaneously hypertensive rats following adolescent atomoxetine treatment.
Baskin BM; Nic Dhonnchadha BÁ; Dwoskin LP; Kantak KM
Psychopharmacology (Berl); 2017 Oct; 234(19):2897-2909. PubMed ID: 28730282
[TBL] [Abstract][Full Text] [Related]
13. A review of the rationale and clinical utilization of α2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders.
Sallee F; Connor DF; Newcorn JH
J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):308-19. PubMed ID: 23782125
[TBL] [Abstract][Full Text] [Related]
14. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
Faraone SV; McBurnett K; Sallee FR; Steeber J; López FA
Clin Ther; 2013 Nov; 35(11):1778-93. PubMed ID: 24139092
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the validity of the use of the spontaneously hypertensive rat as a model of attention deficit hyperactivity disorder in males and females.
Bayless DW; Perez MC; Daniel JM
Behav Brain Res; 2015 Jun; 286():85-92. PubMed ID: 25724583
[TBL] [Abstract][Full Text] [Related]
16. alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data.
Arnsten AF; Scahill L; Findling RL
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):393-406. PubMed ID: 17822336
[TBL] [Abstract][Full Text] [Related]
17. Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
Rizzo R; Martino D
Expert Rev Neurother; 2015 Apr; 15(4):347-54. PubMed ID: 25800130
[TBL] [Abstract][Full Text] [Related]
18. Model of attention deficit hyperactivity disorder: five-trial, repeated acquisition inhibitory avoidance in spontaneously hypertensive rat pups.
Fox GB
Curr Protoc Pharmacol; 2004 Oct; Chapter 5():Unit 5.37. PubMed ID: 22294124
[TBL] [Abstract][Full Text] [Related]
19. Effects of histamine H(3) receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup.
Fox GB; Pan JB; Esbenshade TA; Bennani YL; Black LA; Faghih R; Hancock AA; Decker MW
Behav Brain Res; 2002 Apr; 131(1-2):151-61. PubMed ID: 11844582
[TBL] [Abstract][Full Text] [Related]
20. Glutamate-stimulated release of norepinephrine in hippocampal slices of animal models of attention-deficit/hyperactivity disorder (spontaneously hypertensive rat) and depression/anxiety-like behaviours (Wistar-Kyoto rat).
Howells FM; Russell VA
Brain Res; 2008 Mar; 1200():107-15. PubMed ID: 18295191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
